Overview
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Leah Rosenkrantz, Research Manager
Email Address
Purpose of Study
The purpose of this study is to assess the feasibility of a full-scale, randomized trial to determine whether bloodwork-guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients. Patients will receive either standard of care dosing or dosing with adjustments based on bloodwork to achieve a minimum therapeutic threshold.
Eligible participants will be randomized to one of two groups: standard of care or intervention. In the standard of care group, participants will receive enoxaparin dosed at the discretion of the physician. In the intervention group, participants will receive enoxaparin 0.5 mg/kg twice daily (rounded to the nearest 10 mg) as the initial starting dose. Dose adjustments will be made based on trough anti-Xa levels drawn between the third and fourth dose until the participant is within the target range.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
The purpose of this study is to assess the feasibility of a full-scale, randomized trial to determine whether bloodwork-guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients. Patients will receive either standard of care dosing or dosing with adjustments based on bloodwork to achieve a minimum therapeutic threshold.
Eligible participants will be randomized to one of two groups: standard of care or intervention. In the standard of care group, participants will receive enoxaparin dosed at the discretion of the physician. In the intervention group, participants will receive enoxaparin 0.5 mg/kg twice daily (rounded to the nearest 10 mg) as the initial starting dose. Dose adjustments will be made based on trough anti-Xa levels drawn between the third and fourth dose until the participant is within the target range.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
